-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pyoderma Gangrenosum
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pyoderma Gangrenosum report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pyoderma Gangrenosum Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Sickle Cell Disease Drug Details: Canakinumab (Ilaris / Lasprona...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hypericin Sodium in Mycosis Fungoides
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hypericin Sodium in Mycosis Fungoides report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Hypericin Sodium in Mycosis FungoidesDrug Details:Hypericin (SGX-301, HBP-347) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Goflikicept in Myocardial Infarction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Goflikicept in Myocardial Infarction Drug Details: Goflikicept is under development for the treatment of idiopathic recurrent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Goflikicept in Myocardial Infarction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Goflikicept in Myocardial InfarctionDrug Details:Goflikicept is under development for the treatment of idiopathic recurrent pericarditis, myocardial infarction,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Metastatic Melanoma Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pancreatic Ductal Adenocarcinoma Drug Details: Canakinumab (Ilaris / Lasprona...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Anemia Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Myelodysplastic Syndrome Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro)...